This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bracken MB et al. (1990) A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury: results of the second National Acute Spinal Cord Injury Study. N Engl J Med 322: 1405–1411
Fehlings MG (2001) Recommendations regarding the use of methylprednisolone in acute spinal cord injury: making sense out of the controversy. Spine 26 (Suppl): S56–S57
Qian T et al. (2005) High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients. Spinal Cord 43: 199–203
Geisler FH et al. (2001) Measurements and recovery patterns in a multicenter study of acute spinal cord injury. Spine 26 (Suppl): S68–S86
Fehlings MG and Baptiste DC (2005) Current status of clinical trials for acute spinal cord injury. Injury 36 (Suppl 2): S113–S122
Sharma HS et al. (2005) Neuroprotective effects of nitric oxide synthase inhibitors in spinal cord injury-induced pathophysiology and motor functions: an experimental study in the rat. Ann NY Acad Sci 1053: 422–434
Beattie MS (2004) Inflammation and apoptosis: linked therapeutic targets in spinal cord injury. Trends Mol Med 10: 580–583
Takami T et al. (2002) Methylprednisolone and interleukin-10 reduce gray matter damage in the contused Fischer rat thoracic spinal cord but do not improve functional outcome. J Neurotrauma 19: 653–666
Pearse DD et al. (2004) Transplantation of Schwann cells and olfactory ensheathing glia after spinal cord injury: does pretreatment with methylprednisolone and interleukin-10 enhance recovery? J Neurotrauma 21: 1223–1239
Gorio A et al. (2005) Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. Proc Natl Acad Sci USA 102: 16379–16384
Jones TB et al. (2005) Inflammatory-mediated injury and repair in the traumatically injured spinal cord. Curr Pharm Des 11: 1223–1236
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Sipski is a consultant to ProNeuron Biotechnologies Inc (Los Angeles, CA). Dr Pearse has received research support from Biogen-Idec Inc (Cambridge, MA) and GlaxoSmithKline (Research Triangle Park, NC).
Rights and permissions
About this article
Cite this article
Sipski, M., Pearse, D. Methylprednisolone and other confounders to spinal cord injury clinical trials. Nat Rev Neurol 2, 402–403 (2006). https://doi.org/10.1038/ncpneuro0221
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0221